BioMedNewsBreaks

FridayMar 06, 2026 9:18 am

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Announces Peer-Reviewed Publication Highlighting Pharmacokinetics of TONMYA(TM) Sublingual Tablets 

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced the publication of a peer-reviewed paper detailing results from randomized open-label studies evaluating the pharmacokinetics of TNX-102 SL, the sublingual formulation of cyclobenzaprine HCl marketed as TONMYA(TM). Published in Clinical Pharmacology in Drug Development, the journal of the American College of Clinical Pharmacology, the study highlights how TONMYA’s proprietary basifying agent enables rapid transmucosal absorption that bypasses first-pass hepatic metabolism. The formulation, approved by the U.S. Food and Drug Administration on Aug. 15, 2025, for the treatment of fibromyalgia in adults, is designed to increase parent drug exposure during sleep while reducing exposure to…

Continue Reading

ThursdayMar 05, 2026 9:45 am

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective March 9, 2026

Aditxt (NASDAQ: ADTX), a social innovation platform accelerating promising health innovations, announced it will implement a 1-for-8 reverse stock split of its common stock effective at the opening of trading on March 9, 2026, while continuing to trade on the Nasdaq Capital Market under the symbol ADTX. The reverse split, approved by stockholders at a Feb. 13, 2026 special meeting and finalized by the company’s board of directors, is intended primarily to help the company regain compliance with Nasdaq’s minimum bid price requirement. To view the full press release, visit https://ibn.fm/jBJQ2 About Aditxt Aditxt, Inc. is a social innovation platform…

Continue Reading

ThursdayMar 05, 2026 8:57 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Enrolls First Patients in ALIGN-ACS Pilot Study for Heart Attack Detection 

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the enrollment of the first patients in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The first patients were enrolled by Prof. Dr. Vladan Vukcevic at the University Clinical Center of Serbia in Belgrade, marking a key step toward generating the clinical data needed to expand the HeartBeam System’s indication beyond arrhythmia assessment to include heart attack detection.  To view the full press release, visit https://ibn.fm/636rp  About HeartBeam, Inc.  HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company…

Continue Reading

ThursdayMar 05, 2026 8:56 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Schedules March 12 Conference Call to Review Q4 and Full-Year 2025 Results 

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, will host a conference call at 4:30 p.m. Eastern time on March 12, 2026, to discuss its financial results for the fourth quarter and full year ended Dec. 31, 2025, and provide updates on key strategic growth initiatives, including the limited commercial launch and progress on its 12-lead ECG extended wear patch. A press release detailing the results will be issued prior to the call.  To view the full press release, visit https://ibn.fm/sLaxc  About HeartBeam, Inc.  HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming…

Continue Reading

WednesdayMar 04, 2026 9:10 am

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present Tonmya Data at 2026 AAPM PainConnect Annual Meeting

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced that a poster on Tonmya(TM) (cyclobenzaprine HCl sublingual tablets), investigated as TNX-102 SL, will be presented at the 2026 PainConnect Annual Meeting hosted by the American Academy of Pain Medicine (AAPM). The meeting is scheduled for March 5-8, 2026, in Salt Lake City, Utah, where the Company will share data related to its investigational therapy as part of the scientific program. To view the full press release, visit https://ibn.fm/kwTPM Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology…

Continue Reading

WednesdayMar 04, 2026 9:00 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces Commercial Partnership With ClearCardio as First Customer and Strategic Investor

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced a commercial partnership with ClearCardio(TM), a preventive cardiology practice serving thousands of patients through heart health screening and personalized prevention programs. ClearCardio will serve as HeartBeam’s first commercial customer and plans to make an investment in the company, underscoring strategic alignment. The staged rollout will integrate HeartBeam’s synthesized 12-lead ECG technology into ClearCardio’s cardiac prevention program for arrhythmia assessment, enabling patients to capture clinical-grade ECG readings from home using HeartBeam’s patented cable-free 3D ECG system. Structured as a Letter of Intent outlining subscription-based…

Continue Reading

TuesdayMar 03, 2026 10:40 am

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Exclusive Global License to Three Unleash Immuno-Oncolytics Drug Candidates

TransCode Therapeutics (NASDAQ: RNAZ) announced it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc., obtaining rights to develop three drug candidates — UIO-524, UIO-525 and UIO-526 — including all in-licensed and owned rights held by Unleash. Under the agreement, Unleash will receive a one-time payment of 1,136,364 shares of a new series of non-voting convertible preferred stock, convertible into an equal number of common shares and representing 6.8% of TransCode’s common stock on a fully diluted basis. The lead candidate, UIO-524, is a next-generation oncolytic adenovirus engineered to selectively replicate in malignant…

Continue Reading

TuesdayMar 03, 2026 9:50 am

BioMedNewsBreaks – Gaxos.ai Inc. (NASDAQ: GXAI) Acquires 19.99% Stake in America First Defense to Expand AI-Driven Defense Portfolio

Gaxos.ai (NASDAQ: GXAI) announced it has acquired a 19.99% stake in America First Defense, a U.S.-based defense technology company developing next-generation drone and robotics platforms across air and ground domains. America First Defense is focused on a detachable counter-drone system designed to neutralize hostile UAVs through precise protocol-level cyber attacks and a biomimetic soft robotics platform engineered for low-detection ground and subsurface operations, targeting demand from U.S. defense, homeland security, border security, maritime security, municipal safety and critical infrastructure operators. Gaxos said the investment expands its exposure to American-owned defense innovation and aligns with its strategy to build a diversified…

Continue Reading

MondayMar 02, 2026 9:45 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system, announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer. Dr. Kelley brings more than 20 years of global leadership experience spanning clinical development, translational medicine and regulatory strategy across oncology, rare diseases, CNS and medical devices, having led Phase 1–3 programs and supported regulatory approvals in the United States, Europe, China and Japan. She has previously served as chief medical officer at several biotechnology and medical device companies, including TISSIUM, Servier Pharmaceuticals, X4…

Continue Reading

MondayMar 02, 2026 9:10 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has appointed Prof. Joshua C. Brown, MD, PhD, as Chief Medical Innovation Officer. Prof. Brown is a psychiatrist, neurologist and neuroscientist who studies the mechanisms of Transcranial Magnetic Stimulation (TMS) and their translation into clinical optimization. He serves as Medical Director of the McLean Hospital TMS Service, Director of TMS research and founding director of the Brain Stimulation Mechanisms Laboratory, with more than $20 million in federal funding from the National Institute of Mental Health and the Defense Advanced Research Projects Agency. At NRx, he will support development of mechanistically informed neuropsychiatric…

Continue Reading